Institute of Neurology, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria; Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Neuropathol Appl Neurobiol. 2015 Feb;41(2):e41-55. doi: 10.1111/nan.12185.
We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.
Ki67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens.
Six hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC.
Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores.
本研究旨在对大型脑转移瘤(BM)系列中血管生成和增殖的特征及其与临床特征的相关性进行分析。
通过免疫组化方法测定 BM 和原发肿瘤标本中的 Ki67 增殖指数、微血管密度(MVD)和缺氧诱导因子 1α(HIF-1α)指数。
共纳入 639 例肺癌(344/639;53.8%)、乳腺癌(105/639;16.4%)、黑色素瘤(67/639;10.5%)、肾细胞癌(RCC;52/639;8.1%)或结直肠癌(CRC;71/639;11.1%)患者的 639 例 BM 标本,其中 113 例(17.7%)患者的相应原发肿瘤标本可用于分析。CRC BM 的 Ki67 指数中位数最高,RCC BM 最低(P<0.001)。RCC BM 的 MVD 和 HIF-1α指数最高,黑色素瘤 BM 最低(P<0.001)。乳腺癌、非小细胞肺癌(NSCLC)和 CRC 的 BM 组织中 Ki67 指数、MVD 和 HIF-1α指数明显高于相应的原发肿瘤。对各肿瘤类型的组织学参数与总生存的相关性分析显示,NSCLC BM 中低 Ki67 指数(HR=1.015;P<0.001)和 RCC 中低 Ki67 指数(HR=1.027;P=0.008)和高血管生成活性(HR=1.877;P=0.002)与独立预后相关。
本研究数据表明,BM 患者的原发肿瘤类型之间 Ki67 指数、HIF1-α指数和 MVD 具有不同的病理生物学和临床相关性。NSCLC 和 RCC 患者的 BM 中观察到组织学特征的独立预后影响,支持将这些组织学参数纳入诊断特异性预后评分。